Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health to Acquire Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Tickers ELAN MRK
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers HARP MRK
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.